Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival

International Journal of Cancer

Volumn 123, Issue 4, 2008, Pages 780-786

  Shabo, Ivan ^a   Stål, Olle ^a   Olsson, Hans ^a   Doré, Siv ^a   Svanvik, Joar ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Macrophages; Metastasis; Survival

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; ESTROGEN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; INTERLEUKIN 10; LEUKOCYTE ANTIGEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; GENETICS; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; TUMOR RECURRENCE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; LYMPHATIC METASTASIS; MACROPHAGES; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLOIDIES; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA;

EID: 47049108919     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23527     Document Type: Article

References (58)

1. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
2. Busund LT, Killie MK, Bartnes K, Seljelid R. Spontaneously formed tumorigenic hybrids of Meth A sarcoma cells and macrophages in vivo. Int J Cancer 2003;106:153-9.
3. Larizza L, Schirrmacher V, Pfluger E. Acquisition of high metastatic capacity after in vitro fusion of a nonmetastatic tumor line with a bone marrow-derived macrophage. J Exp Med 1984;160:1579-84.
4. Stover CM, Schleypen J, Gronlund J, Speicher MR, Schwaeble WJ, Holmskov U. Assignment of CD163B, the gene encoding M160, a novel scavenger receptor, to human chromosome 12p13.3 by in situ hybridization and somatic cell hybrid analysis. Cytogenet Cell Genet 2000;90:246-7.
5. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201.
6. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology 2005;210:153-60.
7. Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol 2005;29:617-24.
8. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. Genes encoding structural proteins of epidermal comification and S100 calcium-binding proteins form a gene complex ("epidermal differentiation complex") on human chromosome 1q21. J Invest Dermatol 1996; 106:989-92.
9. Greaves DR, Gordon S. Macrophage-specific gene expression: current paradigms and future challenges. Int J Hematol 2002;76:6-15.
10. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-27.
11. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 2002;7:147-62.
12. Scholl SM, Crocker P, Tang R, Pouillart P, Pollard JW. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis?. Mol Carcinog 1993;7:207-11.
13. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect 1999;1:1275-82.
14. Massague J, Chen YG. Controlling TGF-beta signaling. Gene Dev 2000;14:627-44.
15. Yamate J, Maeda M, Benn SJ, Laithwaite JE, Allan A, Ide M, Kuwamura M, Kotani T, Sakuma S, Lamarre J. Differential effects of transforming growth factor-beta1, a fibrogenic factor, on macrophage-like cells (HS-P) and myofibroblastic cells (MT-9) in vitro. Toxicol Pathol 2001;29:483-91.
16. Pioli PA, Goonan KE, Wardwell K, Guyre PM. TGF-beta regulation of human macrophage scavenger receptor CD163 is Smad3-dependent. J Leukoc Biol 2004;76:500-8.
17. Allavena P, Piemonti L, Longoni D, Bemasconi S, Stoppacciaro A, Ruco L, Mantovani A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28:359-69.
18. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science (New York, NY) 2003;299:1057-61.
19. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000;12:1312-21.
20. Goldstein JI, Goldstein KA, Wardwell K, Fahrner SL, Goonan KE, Cheney MD, Yeager MP, Guyre PM. Increase in plasma and surface CD163 levels in patients undergoing coronary artery bypass graft surgery. Atherosclerosis 2003;170:325-32.
21. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007;9:R15.
22. Austin AS, Judge HM, Robins RA, Cockayne A, Mahida YR. Responses to free lipopolysaccharide and Escherichia coli by normal human intestinal macrophages, following their migration out of the lamina propria. Scand J Immunol 2005;61:575-84.
23. Brandtzaeg P. The new monoclonal antibody (Mac 387) that reacts with macrophages on paraffin sections detects the well-known leukocyte L1 antigen. J Histochem Cytochem 1988;36:1203-6.
24. Brandtzaeg P, Jones DB, Flavell DJ, Fagerhol MK. Mac 387 antibody and detection of formalin resistant myelomonocytic L1 antigen. J Clin Pathol 1988;41:963-70.
25. Fagerhol MK Nomenclature for proteins: is calprotectin a proper name for the elusive myelomonocytic protein?. Clin Mol Pathol 1996; 49:M74-M9.
26. Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N, Takeya M. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006;54:763-71.
27. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004; 122:794-801.
28. Fjellbirkeland L, Cambier S, Broaddus VC, Hill A, Brunetta P, Dolganov G, Jablons D, Nishimura SL. Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue. Am J Pathol 2003; 163:533-42.
29. Amicone L, Terradillos O, Calvo L, Costabile B, Cicchini C, Della Rocca C, Lozupone F, Piacentini M, Buendia MA, Tripodi M. Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation. Oncogene 2002;21:1335-45.
30. Hennessy A, Painter DM, Orange S, Horvath JS. Placental tissue interleukin-10 receptor distribution in pre-eclampsia. Am J Reprod Immunol 2003;49:377-81.
31. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003;228:303-8.
32. Droste A, Sorg C, Hogger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Comm 1999;256:110-3.
33. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000;67:97-103.
34. Ritter M, Buechler C, Kapinsky M, Schmitz G. Interaction of CD163 with the regulatory subunit of casein kinase II (CKII) and dependence of CD163 signaling on CKII and protein kinase C. Eur J Immunol 2001;31:999-1009.
35. Ritter M, Buechler C, Langmann T, Orso E, Klucken J, Schmitz G. The scavenger receptor CD163: regulation, promoter structure and genomic organization. Pathobiology 1999;67:257-61.
36. Duelli D, Lazebnik Y. Cell fusion: a hidden enemy?. Cancer Cell 2003;3:445-8.
37. Friedl P. Cell fusion: new mechanisms of plasticity in cancer? Lancet Oncol 2005;6:916-8.
38. Pawelek JM. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 2005;6:988-93.
39. Vassilopoulos G, Russell DW. Cell fusion: an alternative to stem cell plasticity and its therapeutic implications. Curr Opin Genet Dev 2003;13:480-5.
40. Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, Meyer EM, Morel L, Petersen BE, Scott EW. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 2002;416:542-5.
41. Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe?. Breast Cancer Res 2003;5:89-95.
42. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cane Cell 2006;10:515-27.
43. Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83:249-89.
44. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004;6:171-83.
45. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
46. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
47. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
48. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol 1994;1:173-85.
49. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78:1043-51.
50. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 1996;2:1969-79.
51. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ, King I. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996;184:579-84.
52. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996;88:536-41.
53. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev 2006;17:325-37.
54. Chyczewska E, Mroz RM. Cytokines in lung cancer. Roczniki Akademii Medycznej w Bialymstoku (1995) 1997;42 Suppl 1:8-22.
55. Seo N, Tokura Y, Takigawa M, Egawa K. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999;163:242-9.
56. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007;37:14-6.
57. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993;53:4391-8.
58. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57.